PRIMARY PEPTIDES

By adopting these approaches, we are expanding the pool of undruggable targets. Our goal is to develop a new generation of therapeutics for patients that currently have few options, if any, to treat their diseases effectively... We are a platform company with a clinical stage asset targeting Neuroprotection in Stroke, two assets ready to enter IND enabling studies in Parkinson's Disease targeting alpha synuclein, and ALS targeting TDP-43, as well as a stroke triggered gene vector that will release K13 peptide when a stroke occurs, which is currently in discovery.

Also known as: Primary Peptides Inc.

Primary location: Vancouver Canada